Stay updated on KEYDOX Trial: Doxorubicin & Pembrolizumab in Breast Cancer

Sign up to get notified when there's something new on the KEYDOX Trial: Doxorubicin & Pembrolizumab in Breast Cancer page.
Latest website image capture
Clouds background image

Latest updates to the KEYDOX Trial: Doxorubicin & Pembrolizumab in Breast Cancer page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    Change Detected
    Summary
    Added Revision: v3.4.2 tag and removed the previous government-funding/operating-status notices, while core study content remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.8%
    Check dated 2026-02-11T02:19:33.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    Page updates include a government funding lapse notice indicating NIH Clinical Center status and a Revision: v3.4.1 (replacing v3.4.0); to avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2026-02-04T00:22:51.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    Added a glossary toggle and new footer metadata labels (Results Submitted, Last Update Submitted that Met QC Criteria) and a revision indicator (Revision: v3.4.0). Removed older labels (No Results Posted, Last Update Submitted that met QC Criteria, No FEAR Act data) and the previous revision (v3.3.4).
    Difference
    0.3%
    Check dated 2026-01-27T23:58:50.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    The only visible change is a revision update from v3.3.3 to v3.3.4; there are no changes to the study details, eligibility criteria, or navigation on the page. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-13T17:46:09.000Z thumbnail image
  6. Check
    64 days ago
    Change Detected
    Summary
    Footer updates include a new Revision: v3.3.3 and the removal of the HHS Vulnerability Disclosure link, with Revision: v3.3.2 deleted. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-12-23T08:37:41.000Z thumbnail image
  7. Check
    85 days ago
    Change Detected
    Summary
    Revision: v3.3.2 was added, replacing the previous v3.3.1.
    Difference
    0.1%
    Check dated 2025-12-01T17:23:33.000Z thumbnail image

Stay in the know with updates to KEYDOX Trial: Doxorubicin & Pembrolizumab in Breast Cancer

Enter your email address, and we'll notify you when there's something new on the KEYDOX Trial: Doxorubicin & Pembrolizumab in Breast Cancer page.